Literatur
- 1
Carlo Patrono C, Coller B, Dalen J E, FitzGerald G A. et al .
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects.
CHEST.
2001;
119
39S-63S
- 2
Kallmann R, Nieuwenhuis H K, de Groot P G. et al .
Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane
production and 6-Keto-PGF1a excretion in healthy subjects.
Thromb Res.
1987;
45
355-361
- 3
Antiplatelet Trialists’ Collaboration .
Collaborative overview of randomised trials of antiplatelet therapy I: Prevention
of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various
categories of patients.
BMJ.
1994;
308
81-106
- 4
Valles J, Santos M T, Aznar J. et al .
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin
as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less
than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes
on platelet reactivity.
Circulation.
1998;
97
350-355
- 5
Ridker P M, Cushman M.
Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease
in apparently healthy men.
N Engl J Med.
1997;
336
973-979
- 6
Jarvis B, Simpson K.
Clopidogrel - a review of its use in the prevention of atherothrombosis.
Drugs.
2000;
60
347-377
- 7
McTavish D, Faulds D, Goa K L.
Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent
disorders.
Drugs.
1990;
40
238-259
- 8
Caplain H, D’Honneur G, Cariou R.
Lack of interaction of aspirin (1000 mg) with chronic clopidogrel in volunteers.
Haemostasis.
1996;
26 (Suppl 3)
abstract no 557
- 9
Moshfegh K, Redondo M, Julmy F. et al .
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction.
J Am Coll Cardiol.
2000;
36
699-705
- 10
Auer J, Berent R, Laßnig E. et al .
Thrombozytäre Glykoprotein-IIb/IIIa-Rezeptor-Blocker in der Behandlung der koronaren
Herzkrankheit.
Herz.
2003;
28
393-403
- 11
Sanmuganathan P S, Ghahramani P, Jackson P R. et al .
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit
related to coronary risk derived from meta-analysis of randomised trials.
Heart.
2001;
85
265-271
- 12
Harrington R A, Becker R C, Ezekowitz M. et al .
Antithrombotic therapy for coronary artery disease. The seventh ACCP Conference on
antithrombotic and thrombolytic therapy.
Chest.
2004;
126
513S-548S
- 13
Juul-Möller S, Edvardsson N, Jahmatz B. et al .
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients
with stable chronic angina pectoris. Swedish angina pectoris aspirin trial (SAPAT).
Lancet.
1992;
340
1421-1425
- 14
Ridker P M, Manson J E, Gaziano M. et al .
Low-dose aspirin therapy for chronic stable angina: a randomised, placebo-controlled
clinical trial.
Ann Intern Med.
1991;
114
835-839
- 15
Antiplatelet Trialists’ Collaboration .
Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention
of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various
categories of patients.
BMJ.
1994;
308
81-106
- 16
Dietz R, Rauch B.
Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der
Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (DGK).
Z Kardiol.
2003;
92
501-521
- 17
CAPRIE .
A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of
ischaemic events.
Lancet.
1996;
348
1329-1339
- 18
Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D.
et al .
European Society of Cardiology. Expert consensus document on the use of antiplatelet
agents. The task force on the use of antiplatelet agents in patients with atherosclerotic
cardiovascular disease of the European society of cardiology.
Eur Heart J.
2004;
25 (2)
166-181
- 19
Antithrombotic Trial Collaboration .
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention
of death, myocardial infarction, and stroke in high risk patients.
BMJ.
2002;
324
71-86
- 20
Hamm C W.
Leitlinien: Akutes Koronarsyndrom (ACS) Teil 1: ACS ohne persistierende ST-Hebung.
Z Kardiol.
2004;
93
72-90
- 21
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
.
Effects of Clopidogrel in addition to Aspirin in patients with Acute Coronary Syndromes
without ST-Segment Elevation.
N Engl J Med.
2001;
345
494-502
- 22
ISIS-2 Collaborative Group .
Randomised trial of intravenous streptokinase, oral aspirin, both or neither among
17,187 cases of suspected acute myocardial infarction.
Lancet.
1988;
2
349-360
- 23
Sabatine M S, Cannon C P, Gibson C M. et al .
Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction
with ST-Segment Elevation.
N Engl J Med.
2005;
352
1179-1189
- 24
Doson C, Christopher L, Babor E-M.
Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction.
Letter to the Editor.
N Engl J Med.
2005;
352
2647-2648
- 25
Hamm C W.
Leitlinien: Akutes Koronarsyndrom (ACS) Teil 2: ACS mit persistierender ST-Hebung.
Z Kardiol.
2004;
93
324-341
- 26
The Task Force for Percutaneous Coronary Interventions of the European Society of
Cardiology .
Guidelines for Percutaneous Coronary Interventions.
European Heart Journal.
2005;
26
804-807
- 27
Urban P, Macaya C, Rupprecht H J. et al .
Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary
stent implantation in high risk patients: The multicenter aspirin and ticlopidine
trial after intracoronary stenting (MATTIS).
Circulation.
1998;
98
2126-2132
- 28
Bertrand M E, Rupprecht H, Urban P. et al .
Clopidogrel aspirin stent international cooperative study. CLASSICS.
Circulation.
2000;
102
624-629
- 29
Silber S, Albertsson P, Aviles F F, Camici P G, Colombo A, Hamm C, Jorgensen E. et
al .
Task Force Members. Guidelines for percutaneous coronary interventions: the task force
for percutaneous coronary interventions of the European society of cardiology.
Eur Heart J.
2005;
26 (8)
804-847
- 30
Levy M.
Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer
disease.
N Engl J Med.
1974;
290
1158-1162
- 31
Derry S, Loke Y K.
Risk of gastrointestinal hemorrhage with long term use of aspirin: Meta-analysis.
Br Med J.
2000;
321
1183-1187
- 32
He J, Whelton P K, Vu B. et al .
Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomised controlled trials.
JAMA.
1998;
280
1930-1935
- 33
Hankey G J, Sudlow C LM, Dunbabin D W.
Thienopyridines or aspirin to prevent stroke and other serious vascular events in
patients at high risk of vascular disease? A systematic review of the evidence from
randomized trials.
Stroke.
2000;
31
1779-1784
- 34
Bennett C L, Connors J M, Carwile J M. et al .
Thrombotic thrombocytopenic purpura associated with clopidogrel.
N Engl J Med.
2000;
342
1773-1777
- 35
The EPIC Investigators .
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor
in high-risk coronary angioplasty.
N Engl J Med.
1994;
330
956-961
- 36
Patrono C.
Aspirin resistance: definition, mechanisms and clinical read-outs.
J Thromb Haemost.
2003;
1
1710-1713
- 37
Geiger J, Teichmann L, Grossmann R. et al .
Monitoring of Clopidogrel Action: Comparison of Methods.
Clinical Chemistry.
2005;
51(6)
957-965
- 38
Grotemeyer K H, Scharafinski H W, Husstedt I W.
Two year follow-up of aspirin responder and aspirin non responder. A pilot study including
180 poststroke patients.
Thromb Res.
1993;
71
397-403
- 39
Gum P A, Kottke-Marchant K, Welsh P A, White J, Topol E J.
A prospective, blinded determination of the natural history of aspirin resistance
among stable patients with cardiovascular disease.
J Am Coll Cardiol.
2003;
41
961-965
- 40
Barragan B, Bouvier J-L, Roquebert P-O, Macaluso G, Commeau P, Comet B, Lafont A,
Camoin L, Walter U, Eigenthaler M.
Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by
Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation.
Cathet Cardiovasc Intervent.
2003;
59
295-302
Dr. med. Felix Post
II. Medizinische Klinik und Poliklinik
Klinikum der Johannes Gutenberg-Universität · Langenbeckstr. 1 · 55131 Mainz
eMail: post@2-med.klinik.uni-mainz.de
